Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable tech could spot Post-Surgery problems early

NCT ID NCT04596384

Symptom relief Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether a home-based telemonitoring program, which tracks symptoms and daily steps using a wearable device and app, can improve recovery and reduce complications within 30 days after abdominal surgery for gastrointestinal, genitourinary, or gynecologic cancers. Participants are randomly assigned to either the telemonitoring program or standard surgeon-only care. The study measures changes in daily step count, post-operative complications, and time to hospital readmission to see if early detection of problems can lead to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Home-based telemonitoring program using a wearable activity tracker and symptom reporting app
What this could lead to
If effective, this approach could help doctors detect and treat post-surgery problems early, improving recovery and reducing complications for cancer patients.
What could go wrong
The trial is early and may not show a clear benefit. Patients may find the technology burdensome, and results may not apply to all types of surgery or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

398 people

The number who actually took part.

Started

Feb 2021

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cancer patients scheduled to undergo major abdominal surgery for gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) malignancies * Ability to read and understand English or Spanish * Patients across all stages of disease * There are no restrictions related to performance status or life expectancy * All subjects must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digestive system carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer digestive system carcinoma female reproductive organ cancer malignant urinary system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Digestive system carcinoma Genitourinary system carcinoma Malignant female reproductive system neoplasm Malignant solid neoplasm

Contacts and locations

Locations

  • City of Hope Antelope Valley

    Lancaster, California, 93534, United States

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • City of Hope South Pasadena

    South Pasadena, California, 91030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.